Battle looms at Biogen as Icahn seeks board seats
480264
Billionaire investor Carl Icahn said on Monday he is seeking three seats on the board of Biogen Idec Inc , setting the stage for a battle for control of one of the world's biggest biotechnology companies.
30782
Billionaire shareholder activist Carl Icahn raised his stake in BEA Systems, as he ramps up the pressure to push the company's board into selling the enterprise applications software maker.
588024
Financier Carl Icahn on Friday offered to buy the shares of generic drugmaker Mylan Laboratories  that he does not already own for &#36;4.9 billion, or &#36;20 a share, according to a government filing.
697697
A takeover attempt follows management shakeups at the biopharmaceutical firm.
425366
Pharmaceutical stocks were in the spotlight Thursday with news that investor Carl Icahn&#39;s was given a green light to buy a sizable chunk of Mylan Laboratories Inc.
507775
By Tricia Bishop, The Baltimore Sun  Dec. 14--One of MedImmune Inc.'s major shareholders is urging the state's flagship biotech to put itself up for sale, suggesting management hasn't made the most from its assets, which include four products on the market and about 40 in the pipeline.
162635
Billionaire investor Carl Icahn said   on Thursday that he will seek approval from ImClone Systems   Inc. IMCL.O stockholders to remove some directors from its   board and to fill one of the vacancies with his own nominee.
97449
Investor Carl Icahn on Thursday detailed his objections to Mylan Laboratories Inc.&#39;s proposed $4 billion acquisition of King Pharmaceuticals Inc.
432855
Biogen Idec in Cambridge is rumored to be in talks to buy or merge with Elan Corp. in Ireland, though the later company denies any such conversation is taking place, Bloomberg News is reporting.
654609
Genzyme and Millenium vie to purchase the Canadian biotech.
5889
As the Massachusetts Biotechnology Council's new leader faces ethics questions, some members say they have become disenchanted with the trade group, including its increasing focus on lobbying, a high staff turnover rate, and the low number of top executives serving on its board.
260832
BOSTON  â The investor Carl C. Icahn said on Monday that he was trying to get three supporters elected to the board of the biotechnology firm Biogen Idec because of concerns over the sales process.
608460
ImClone Systems Inc. IMCL.O   shareholders on Wednesday elected Carl Icahn and two of his   associates to its board in the hope the billionaire investor   can help stabilize the company after a series of blows that   could hurt sales and limit its strategic options.
459578
US billionaire investor Carl Icahn is looking to win a seat on Motorola's board, the mobile phone maker says.
386076
In a letter to the board of directors at Mylan Laboratories (nyse: MYL - news - people ), financier Carl Icahn questioned their silence on the recent financial restatements by King Pharmaceuticals (nyse: KG - news - people ), calling the &quot;lack of
463623
James C. Mullen,Biogen Idec Inc.Chief executive For Biogen Idec Inc., the return of the multiple sclerosis drug Tysabri to the market and continued sales growth for its cash cow, Avonex, were the highlights of 2006. Chief executive James C. Mullen recently spoke with Globe reporter Jeffrey Krasner about the company's progress and the challenges posed by the 2006 election.
567020
U.S. drug company Biogen Idec is considering an all-share bid of more than 8.5 billion euros (&#36;10.6 billion) for Irish peer Elan, a newspaper reported on Sunday.